Announcement for BioArctic's Upcoming Presentation
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) is excited to announce that it will release its fourth quarter financial report for the period of October to December 2025 on an expected date in February.
What's on the Agenda?
On the day of the report's release, the company invites investors, analysts, and media experts to tune into a detailed presentation. This session will be hosted by Gunilla Osswald, the CEO, alongside Anders Martin-Löf, the CFO, and other team members who will provide insights into the quarterly results followed by a Q&A segment.
Webcast Participation
Interested parties can engage in the presentation through a webcast. During this event, attendees will have the opportunity to submit their questions in writing, enabling a comprehensive interaction regarding the topics discussed.
Teleconference Details
For those who prefer to join via teleconference, there will be a registration process in place. Once registered, participants will receive telephone numbers and a unique conference ID essential for joining. Questions can be asked verbally during the teleconference to foster a more interactive experience.
Post-Presentation Access
Those who miss the live presentation can catch up later, as the webcast will be recorded and made available on BioArctic's corporate website for continual access.
About BioArctic AB
Founded in Sweden, BioArctic AB is a biopharmaceutical company that prioritizes research and innovative solutions aimed at combatting neurodegenerative diseases. Among its achievements is the creation of Leqembi (lecanemab), recognized as the first treatment shown to effectively slow the progression of early Alzheimer's disease and mitigate cognitive decline. This groundbreaking drug has been developed in partnership with Eisai and represents a significant milestone in medical advancement.
Research and Development Initiatives
In addition to Leqembi, BioArctic is actively expanding its research portfolio. The company is investigating treatments for Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). A number of initiatives leverage the proprietary BrainTransporter™ technology which aims to improve the delivery of therapeutic antibodies through the blood-brain barrier, aiming for enhanced treatment outcomes in patients.
For More Information
For further inquiries, stakeholders can reach out to Oskar Bosson, VP Communications at BioArctic, for any communication-related queries. Alternately, Jenny Ljunggren, as the External Communications Manager, is available for investor relations discussions.
Frequently Asked Questions
What date is BioArctic's fourth quarter report scheduled for?
The fourth quarter report is expected to be released in February.
Who will lead the presentation during the event?
The presentation will be led by Gunilla Osswald, the CEO, and Anders Martin-Löf, the CFO.
Can participants submit questions during the presentation?
Yes, attendees can submit written questions during the webcast.
What is Leqembi?
Leqembi is BioArctic’s innovative therapy for early Alzheimer's disease, noted for its ability to slow disease progression.
How can I access the webcast after the event?
The webcast will be available on BioArctic's website post the presentation for those who wish to view it later.
